Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Johnson & Johnson
(NY:
JNJ
)
146.14
-0.68 (-0.46%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Johnson & Johnson
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
March 13, 2024
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into...
Via
Benzinga
Exposures
Product Safety
Analyzing NYSE:JNJ's Dividend Potential.
March 13, 2024
Why JOHNSON & JOHNSON (NYSE:JNJ) qualifies as a good dividend investing stock.
Via
Chartmill
3 No-Brainer Stocks to Buy With $300 Right Now
March 13, 2024
A reasonably modest amount of money can go a long way when it's put to work in historically cheap, industry-leading businesses.
Via
The Motley Fool
7 High-Quality Blue-Chip Stocks to Buy if You’re Looking for Stability
March 12, 2024
With the market facing a possible rotation out of hot tech names, these stable blue-chip stocks may offer investors confidence.
Via
InvestorPlace
Golden Cross Alert: Johnson & Johnson Shines With Ambrx Deal, Bullish Technical Signal
March 12, 2024
Johnson & Johnson stock down 1.22% in 6 months, up 5.57% in a year, and 3% YTD. Recent acquisition of Ambrx Biopharma boosts stock. Golden Cross signals trend reversal.
Via
Benzinga
Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector
March 11, 2024
Via
Benzinga
Johnson & Johnson Unusual Options Activity For March 08
March 08, 2024
Via
Benzinga
Smart Money Is Betting Big In JNJ Options
March 05, 2024
Via
Benzinga
3 Must-Have Dividend Kings for a Steady Income Stream
March 12, 2024
Discover the dividend kings with constant growth, dominating pharmaceuticals, household products and biotechnology industries.
Via
InvestorPlace
2 High-Yield Dow Jones Dividend Stocks to Buy Now and Hold Forever
March 12, 2024
These industry leaders boast advantages that could expand their bottom lines for decades.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
March 11, 2024
From
Johnson & Johnson
Via
Business Wire
The Dow’s Best Friends: 3 ‘Dogs’ Ready to Fetch Huge Returns
March 11, 2024
The Dogs of the Dow strategy is one of the best yearly strategies investors should use to make some good money.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Wall Street Favorites: Why Analysts Love These 3 Blue-Chip Stocks
March 11, 2024
Blue-chip stocks are known for their quality, stablility and consistency, which you'll find in all three of these top-notch growth stocks.
Via
InvestorPlace
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
March 11, 2024
These are some of the best-performing stocks in what's arguably society's most important industry.
Via
The Motley Fool
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
March 09, 2024
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung...
Via
Talk Markets
Exposures
Product Safety
The Top 3 Pharma Stocks to Buy in March2024
March 09, 2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge.
Via
InvestorPlace
3 Dividend Aristocrat Stocks to Buy And Hold: March 2024
March 08, 2024
Buy-and-holder investors should fill their portfolios with these dividend aristocrat stocks to buy. These are some of the top names in the market.
Via
InvestorPlace
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.
Via
Benzinga
The Top 3 Healthcare Stocks to Buy in March 2024
March 07, 2024
There are still bargains to be had in the medical space. These are three top healthcare stocks to buy today.
Via
InvestorPlace
The Top 3 Blue-Chip Stocks to Buy in March 2024
March 07, 2024
Wager on these top blue-chip stocks to buy, striking an ideal balance between stability and growth for savvy long-term investors.
Via
InvestorPlace
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
March 07, 2024
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,...
Via
Benzinga
Johnson & Johnson Completes Acquisition of Ambrx
March 07, 2024
From
Johnson & Johnson
Via
Business Wire
The Top 7 Dividend Stocks to Buy in March 2024
March 06, 2024
Bet on these top dividend stocks to buy for a resilient income flow and steady market gains, offering excellent balance.
Via
InvestorPlace
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
March 05, 2024
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world.
Via
Benzinga
7 No-Frills Dividend Stocks for Your Must-Own List
March 05, 2024
Income investors don't need to invest in risky businesses when no-frills dividend stocks get the job done just fine.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
March 04, 2024
Via
Benzinga
Secure Your Future: 7 Dividend Kings with Solid Growth Potential
March 04, 2024
Here are seven dividend kings that manage to deliver market-beating stock price growth in addition to their reliable, growing dividends.
Via
InvestorPlace
Will Johnson & Johnson Be a Trillion-Dollar Stock by 2030?
March 03, 2024
Can Johnson & Johnson stock become a hot buy for growth-focused investors, or is this mainly just a dividend play?
Via
The Motley Fool
Johnson & Johnson Jump?
March 01, 2024
Johnson and Johnson is coming into a strong seasonal pattern now with an average return of nearly 5%.
Via
Talk Markets
Don’t Panic! 7 Smart Stocks to Buy if the Markets Take a Tumble.
February 29, 2024
No one wants the red ink to start flying right now. However, if it does, these are the stocks to buy for a down market.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.